葵花药业
(002737)
| 流通市值：75.92亿 | | | 总市值：75.92亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 843,918,908.69 | 2,317,958,832.5 | 1,683,984,047.39 | 1,310,143,325.88 |
| 营业收入 | 843,918,908.69 | 2,317,958,832.5 | 1,683,984,047.39 | 1,310,143,325.88 |
| 二、营业总成本 | 690,471,907.04 | 2,580,394,835.96 | 1,747,427,250.48 | 1,236,684,721.22 |
| 营业成本 | 368,489,890.82 | 1,433,608,656.58 | 1,049,911,737.15 | 801,110,342.62 |
| 税金及附加 | 11,988,229.33 | 39,474,148.63 | 28,130,414.92 | 21,302,196.35 |
| 销售费用 | 208,087,977.94 | 580,118,065.89 | 336,479,049.08 | 186,841,827.19 |
| 管理费用 | 78,421,411.06 | 420,071,662.05 | 270,722,708.22 | 185,375,087.68 |
| 研发费用 | 23,410,553.19 | 111,110,079.52 | 66,107,740.22 | 45,181,639.23 |
| 财务费用 | 73,844.7 | -3,987,776.71 | -3,924,399.11 | -3,126,371.85 |
| 其中:利息费用 | 882,045.31 | 3,692,854.18 | 1,219,173.87 | 775,594.83 |
| 其中:利息收入 | 1,055,407.43 | 8,459,212.5 | 5,569,374.47 | 4,285,751.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -8,710,366.12 | 3,891,722.08 | 5,084,930.96 | 5,812,389.88 |
| 加:投资收益 | 9,412,245.75 | 31,048,755.67 | 19,675,919.34 | 10,371,400.62 |
| 资产处置收益 | -78,965.14 | -654,459.15 | 652,556.91 | 653,722.6 |
| 资产减值损失(新) | -17,984,407.52 | -83,665,900.79 | -6,839,558.04 | -3,898,447.14 |
| 信用减值损失(新) | -2,300,335.74 | 6,237,385.6 | -3,170,015.65 | -3,625,190.49 |
| 其他收益 | 6,399,326.25 | 54,389,967.59 | 50,388,599.86 | 35,245,703.07 |
| 四、营业利润 | 140,184,499.13 | -251,188,532.46 | 2,349,230.29 | 118,018,183.2 |
| 加:营业外收入 | 1,588,617.24 | 1,710,900.71 | 124,113.98 | 49,921.96 |
| 减:营业外支出 | 285,878.32 | 21,677,073.92 | 8,708,107.01 | 5,606,293.66 |
| 五、利润总额 | 141,487,238.05 | -271,154,705.67 | -6,234,762.74 | 112,461,811.5 |
| 减:所得税费用 | 25,695,173.67 | 25,918,595.84 | 39,679,584.12 | 30,891,877.05 |
| 六、净利润 | 115,792,064.38 | -297,073,301.51 | -45,914,346.86 | 81,569,934.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 115,792,064.38 | -297,073,301.51 | -45,914,346.86 | 81,569,934.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 110,285,854.48 | -257,827,575.47 | -33,538,693.69 | 81,309,905.41 |
| 少数股东损益 | 5,506,209.9 | -39,245,726.04 | -12,375,653.17 | 260,029.04 |
| 扣除非经常损益后的净利润 | 106,126,539.85 | -309,535,978.07 | -81,393,930.98 | 48,185,456.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.19 | -0.44 | -0.06 | 0.14 |
| (二)稀释每股收益 | 0.19 | -0.44 | -0.06 | 0.14 |
| 八、其他综合收益 | - | 41,865.61 | -26,732.16 | 26,732.16 |
| 归属于母公司股东的其他综合收益 | - | 29,305.93 | -18,712.51 | 18,712.51 |
| 九、综合收益总额 | 115,792,064.38 | -297,031,435.9 | -45,941,079.02 | 81,596,666.61 |
| 归属于母公司股东的综合收益总额 | 110,285,854.48 | -257,798,269.54 | -33,557,406.2 | 81,328,617.92 |
| 归属于少数股东的综合收益总额 | 5,506,209.9 | -39,233,166.36 | -12,383,672.82 | 268,048.69 |
| 公告日期 | 2026-04-30 | 2026-04-27 | 2025-10-28 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |